Swiss drugmaker Roche has won approval from U.S. antitrust authorities for its $4.3 billion bid to acquire gene therapy specialist Spark Therapeutics. The development clears the way for Roche’s strategic push to position itself in the treatment of rare diseases,… Read More ›
The decision comes in the wake of continuing regulatory scrutiny by antitrust regulators in the UK and U.S. over its takeover offer. Following a continuation of regulatory reviews in the United States and Britain, Roche and Spark Therapeutics announced another… Read More ›
manageria.biz 